Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040325 | 0.75 | DGAT1 (0.33) | KDR | |
| SCHEMBL18237574 | 0.75 | CYP11B1 (0.37) | KDR | |
| SCHEMBL10281635 | 0.72 | CCR1 (0.33) | HTTCYP2C9SRCCYP2E1CYP2A6 | |
| SCHEMBL18609179 | 0.72 | PIK3CA (0.51) | TGFBR1KDRHTT | |
| SCHEMBL19225581 | 0.71 | GPR139 (0.34) | GPR139 | |
| SCHEMBL15510855 | 0.71 | HDAC8 (0.34) | KDR | |
| SCHEMBL16566714 | 0.71 | CYP2A6 (0.35) | KDRCYP2A6 | |
| SCHEMBL17563254 | 0.70 | KDM4E (0.33) | TGFBR1KDRCYP1A2CYP2A6 | |
| SCHEMBL2653313 | 0.69 | KDR (0.60) | KDRSRCMKNK1 | |
| SCHEMBL3312349 | 0.69 | TGFBR1 (0.39) | TGFBR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137034-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9126943-B2 | Nitrogenated heterocyclic ring derivative and organic electroluminescent element comprising same | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126943-B2 | Nitrogenated heterocyclic ring derivative and organic electroluminescent element comprising same | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150051179-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8791095-B2 | Steroidal CYP17 inhibitors/antiandrogens | TOKAI PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120283296-A1 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | AFRAXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8131527-B1 | FGFR pharmacophore compounds | ASTEX THERAPEUTICS LTD. (GB) | 2012-03-06 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | TGFBR1 3128/4885KDR 4201/4885HTT 2816/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | TGFBR1 3659/4885KDR 999/4885HTT 1898/4885 |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | H1-2, L1CAM, H1-0 | TGFBR1 576/4885KDR 691/4885HTT 1594/4885 |
| US-20150051179-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | TGFBR1 3128/4885KDR 4201/4885HTT 2816/4885 |
| US-20120283296-A1 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | PAK2, PAK3, PAK5 | TGFBR1 4868/4885KDR 1774/4885HTT 1563/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | TGFBR1 3314/4885KDR 821/4885HTT 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.